NZ595629A - Methods for preventing and/or treating lysosomal storage disorders - Google Patents
Methods for preventing and/or treating lysosomal storage disordersInfo
- Publication number
- NZ595629A NZ595629A NZ595629A NZ59562910A NZ595629A NZ 595629 A NZ595629 A NZ 595629A NZ 595629 A NZ595629 A NZ 595629A NZ 59562910 A NZ59562910 A NZ 59562910A NZ 595629 A NZ595629 A NZ 595629A
- Authority
- NZ
- New Zealand
- Prior art keywords
- preventing
- lysosomal storage
- methods
- storage disorders
- treating lysosomal
- Prior art date
Links
- 208000015439 Lysosomal storage disease Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 208000015872 Gaucher disease Diseases 0.000 abstract 1
- 208000014060 Niemann-Pick disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16810909P | 2009-04-09 | 2009-04-09 | |
| PCT/US2010/030472 WO2010118283A1 (en) | 2009-04-09 | 2010-04-09 | Methods for preventing and/or treating lysosomal storage disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ595629A true NZ595629A (en) | 2013-04-26 |
Family
ID=42934559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ595629A NZ595629A (en) | 2009-04-09 | 2010-04-09 | Methods for preventing and/or treating lysosomal storage disorders |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8940766B2 (https=) |
| EP (1) | EP2416656B1 (https=) |
| JP (1) | JP5645918B2 (https=) |
| CN (1) | CN102625661B (https=) |
| AU (1) | AU2010233188B2 (https=) |
| BR (1) | BRPI1010517A2 (https=) |
| CA (1) | CA2758271C (https=) |
| ES (1) | ES2564093T3 (https=) |
| IL (1) | IL215583A (https=) |
| NZ (1) | NZ595629A (https=) |
| WO (1) | WO2010118283A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2932982B1 (en) | 2005-05-17 | 2018-10-03 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
| CA2758187C (en) * | 2009-04-09 | 2017-03-07 | Robert Boyd | Methods for preventing and/or treating degenerative disorders of the central nervous system |
| SI2490532T1 (sl) | 2009-10-19 | 2017-03-31 | Amicus Therapeutics, Inc. | Novi sestavki za preventivo in/ali zdravljenje degenerativnih motenj centralnega živčnega sistema |
| WO2011049737A1 (en) | 2009-10-19 | 2011-04-28 | Amicus Therapeutics, Inc. | Novel compositions for preventing and/or treating lysosomal storage disorders |
| KR20200032244A (ko) * | 2012-03-07 | 2020-03-25 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물 |
| ES2771849T3 (es) * | 2014-02-12 | 2020-07-07 | Amicus Therapeutics Inc | Derivados de azúcares que comprenden restos que contienen azufre, métodos para prepararlos y métodos para emplearlos en el tratamiento de MPS IIIC |
| WO2016054231A1 (en) | 2014-09-30 | 2016-04-07 | Amicus Therapeutics, Inc. | Highly potent acid alpha-glucosidase with enhanced carbohydrates |
| KR102510941B1 (ko) | 2015-12-30 | 2023-03-20 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병 치료용의 강화된 산 알파-글루코시다제 |
| IL325155A (en) | 2016-03-30 | 2026-02-01 | Amicus Therapeutics Inc | Formulations containing recombinant acid alpha-glucosidase |
| US10227577B2 (en) | 2016-03-30 | 2019-03-12 | Amicus Therapeutics, Inc. | Method for selection of high M6P recombinant proteins |
| EP3624831B1 (en) | 2017-05-15 | 2023-03-29 | Amicus Therapeutics, Inc. | Recombinant human acid alpha-glucosidase |
| US20220184185A1 (en) | 2018-07-25 | 2022-06-16 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4407957A (en) | 1981-03-13 | 1983-10-04 | Damon Corporation | Reversible microencapsulation of a core material |
| CA2109085C (en) | 1991-04-25 | 2003-03-11 | Keith E. Dionne | Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
| ES2179831T3 (es) | 1992-09-29 | 2003-02-01 | Inhale Therapeutic Syst | Liberacion en los pulmones de fragmentos activos de hormona paratiroidiana. |
| WO1995024391A1 (en) * | 1994-03-09 | 1995-09-14 | Novo Nordisk A/S | Piperidines and pyrrolidines |
| FR2718357B1 (fr) | 1994-04-06 | 1997-10-03 | Defarges Alain Moreau | Perfectionnements apportés à un dispositif d'injection par jet sans aiguille. |
| US5844102A (en) | 1994-07-07 | 1998-12-01 | University Of Maryland Baltimore County | Glycohydrolase inhibitors, their preparation and use thereof |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
| US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
| US20040204379A1 (en) | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US20060079533A1 (en) * | 2001-03-23 | 2006-04-13 | Nieman James A | Methods of treating alzheimer's disease |
| JP2006507359A (ja) | 2002-10-28 | 2006-03-02 | ノボ・ノルデイスク・エー／エス | 心循環器疾患の治療のためのグリコーゲンホスホリラーゼ阻害剤の使用 |
| US7446098B2 (en) | 2003-02-18 | 2008-11-04 | Mount Sinai School Of Medicine Of New York University | Combination therapy for treating protein deficiencies |
| EP1682504B1 (en) * | 2003-11-12 | 2012-12-26 | Amicus Therapeutics Inc. | Hydroxy piperidine derivatives to treat gaucher disease |
| JP5303458B2 (ja) * | 2006-06-23 | 2013-10-02 | アミークス セラピューティックス インコーポレイテッド | β−グルコセレブロシダーゼの活性増強による神経学的疾患の治療方法 |
| EP2150254A4 (en) | 2007-04-26 | 2010-11-10 | Amicus Therapeutics Inc | DOSAGES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES WITH PHARMACOLOGICAL CHAPTERONES |
| US8321148B2 (en) | 2008-10-24 | 2012-11-27 | Amicus Therapeutics, Inc. | Multiple compartment dosing model |
| CA2758187C (en) * | 2009-04-09 | 2017-03-07 | Robert Boyd | Methods for preventing and/or treating degenerative disorders of the central nervous system |
-
2010
- 2010-04-09 US US12/757,160 patent/US8940766B2/en active Active
- 2010-04-09 CN CN201080023544.XA patent/CN102625661B/zh not_active Expired - Fee Related
- 2010-04-09 WO PCT/US2010/030472 patent/WO2010118283A1/en not_active Ceased
- 2010-04-09 CA CA2758271A patent/CA2758271C/en not_active Expired - Fee Related
- 2010-04-09 JP JP2012504881A patent/JP5645918B2/ja not_active Expired - Fee Related
- 2010-04-09 NZ NZ595629A patent/NZ595629A/xx not_active IP Right Cessation
- 2010-04-09 EP EP10762469.4A patent/EP2416656B1/en not_active Not-in-force
- 2010-04-09 AU AU2010233188A patent/AU2010233188B2/en not_active Ceased
- 2010-04-09 BR BRPI1010517A patent/BRPI1010517A2/pt not_active Application Discontinuation
- 2010-04-09 ES ES10762469.4T patent/ES2564093T3/es active Active
-
2011
- 2011-10-06 IL IL215583A patent/IL215583A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| IL215583A (en) | 2016-09-29 |
| JP5645918B2 (ja) | 2014-12-24 |
| EP2416656A4 (en) | 2012-09-05 |
| CA2758271A1 (en) | 2010-10-14 |
| CN102625661B (zh) | 2015-05-27 |
| AU2010233188A1 (en) | 2011-11-03 |
| US20100260740A1 (en) | 2010-10-14 |
| EP2416656A1 (en) | 2012-02-15 |
| BRPI1010517A2 (pt) | 2017-01-31 |
| WO2010118283A1 (en) | 2010-10-14 |
| CN102625661A (zh) | 2012-08-01 |
| CA2758271C (en) | 2018-06-05 |
| US8940766B2 (en) | 2015-01-27 |
| JP2012523431A (ja) | 2012-10-04 |
| EP2416656B1 (en) | 2015-12-23 |
| AU2010233188B2 (en) | 2015-07-16 |
| ES2564093T3 (es) | 2016-03-17 |
| IL215583A0 (en) | 2011-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ595629A (en) | Methods for preventing and/or treating lysosomal storage disorders | |
| NZ595630A (en) | Methods for preventing and/or treating degenerative disorders of the central nervous system | |
| IL180565A0 (en) | An improved stopcock for administering medicaments into the patient's body | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| JP2012523431A5 (https=) | ||
| BRPI1011031A2 (pt) | sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste. | |
| IL249715B (en) | N-butyl-deoxynojirimycin for use as a drug for the treatment of Pompe disease in combination with an enzyme replacement therapy agent | |
| WO2011009020A3 (en) | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers | |
| IL217901B (en) | Use of laquinimod or a laquinimod salt in the manufacture of a drug for the treatment of bdnf-related diseases | |
| PH12012501480A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| HK1199726A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| NZ598145A (en) | Folate-targeted diagnostics and treatment | |
| WO2012027065A3 (en) | Combination therapy for treatment of disease | |
| WO2008088537A3 (en) | Stent with a coating for delivering a therapeutic agent | |
| WO2011085256A3 (en) | Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent | |
| AU2012286851A8 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| MY166890A (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| HK1197276A1 (en) | Methods and compositions for the treatment and diagnosis of bladder cancer | |
| WO2011019963A3 (en) | Prg4 treatment for interstitial cystitis | |
| SG141358A1 (en) | Treatment of psychiatric patients with reduced heptaic function with paliperidone | |
| IL208751A0 (en) | Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood | |
| MY169579A (en) | Use of a composition comprising formoterol and beclometasone dipropionate for the treatment of an exacerbation of asthma | |
| DK2319517T3 (da) | Anvendelse af prodrugs til okulær, intravenøs administration | |
| WO2007133796A3 (en) | Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist | |
| WO2011050008A9 (en) | Combination therapy comprising administration of an amylinomimetic and a pyy peptidomimetic for effecting weight loss and for treating obesity and related metabolic conditions and disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ERR | Error or correction |
Free format text: THE AGENT HAS BEEN CORRECTED TO 1441794, IPONZ, 2. , 205 VICTORIA STREET, TE ARO, WELLINGTON 6011, NZ; 1028818, WRAYS, WRAYS #1701, 24B MOOREFIELD ROAD, JOHNSONVILLE, WELLINGTON 6037, NZ Effective date: 20130327 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 09 APR 2017 BY CPA GLOBAL Effective date: 20140306 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 APR 2018 BY CPA GLOBAL Effective date: 20170303 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 APR 2019 BY CPA GLOBAL Effective date: 20180301 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 APR 2020 BY CPA GLOBAL Effective date: 20190307 |
|
| LAPS | Patent lapsed |